Thirty years of
aptamer research.
Now potentially commercially deployable
for the first time.

A short, synthetic strand of DNA or RNA that folds into a precise three-dimensional shape. That shape allows it to bind: with extraordinary selectivity: to a specific target: a protein, a pathogen, a toxin, a cancer biomarker. Think of it as a molecular key cut precisely for one lock.

Antibodies are biological: grown in animals or cell cultures, expensive to manufacture, and slow to adapt to new variants. Aptamers are synthetic: made by chemical synthesis, stable at room temperature, cheaper to produce at scale, and can be optimized to bind to a new target in weeks.

Aptamers can be engineered as multivalent constructs: multiple binding arms on a single molecule: that lock onto a target from multiple angles simultaneously. Triera's homotrimeric and multivalent trident aptamer families exploit this architecture to achieve binding strength and specificity that no single-site antibody can match.

The fundamental science has been published for thirty years. The barrier was not the biology: it was the full-stack capability to go from aptamer discovery through sensor engineering, ML-based signal classification, and clinical validation in a single team. Triera has assembled that capability.